Trial intelligence / Profile preview

AR-15512 in Dry Eye Disease

NCT06544707Phase 3Completed

Sponsor
Alcon Inc.
Start
Oct 2024
Primary completion
Jan 2025
Countries
1
01

Overview

A Phase 3 trial of acoltremon in dry eye disease (DED), sponsored by Alcon Inc.. Started Oct 2024; status: completed.

02

Drugs

acoltremon
03

Conditions

dry eye disease (DED)

Beyond the preview

Go deeper on NCT06544707.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06544707.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call